LTRN צמיחת רווחי EPS רבעונית Lantern Pharma

Lantern Pharma Inc. (LTRN) monetizes AI technologies by receiving payments for the development of personalized oncology drugs. The firm's strategy is based on expansion within the targeted therapy segment and the acceleration of LP-300 trials. Low geopolitical risks in the US ensure the stability of research. The current quarterly EPS growth value demonstrates profit dynamics, where -42.10 shows the value of this parameter on the chart.
LTRN (Lantern Pharma): פילוחים אנליטיים ודוחות לפי אינדיקטורים

For Lantern Pharma Inc. (LTRN), which utilizes machine learning to develop cancer therapies, the quarterly change in earnings per share reflects the efficiency of monetizing its intellectual databases. This indicator is calculated as the percentage deviation of the current EPS from the value of the same period last year, measuring the business's ability to generate real returns on capital and hedge against inflationary risks.